MDSCs with increased indoleamine 2,3-dioxygenase (IDO) activity are more common in chronic lymphocytic leukemia (CLL) patients, suppressing the activation of T cells and inducing suppressive Treg cells. Here, IDO2 is linked to B-cell chronic lymphocytic leukemia.